A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas This is an ASCO Meeting Abstract ...
BioWorld - Tuesday, June 2, 2026 Breaking News: Ongoing coverage of the Ebola outbreak See today's BioWorld Science Home » DR5 as promising CAR T-cell target allowing inhibition of tumor cells and ...
A new twist on a decades-old anticancer strategy has shown powerful effects against multiple cancer types in a preclinical study from researchers in the Perelman School of Medicine at the University ...
University of Pennsylvania researchers investigated death receptor 5 (DR5 or CD262) as a chimeric antigen receptor (CAR) target for solid tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results